Skip to main content

Advertisement

Table 1 The clinical features of gastric cancer patients in the model group and validation group

From: Integrated analysis reveals potential long non-coding RNA biomarkers and their potential biological functions for disease free survival in gastric cancer patients

  Model group (n = 265) Validation group (n = 300) P value
Death [n (%)] 98 (37.0) 161 (53.7) < 0.001
Survival time (mean ± SD, month) 20.6 ± 18.8 33.7 ± 29.8 0.008
Age (mean ± SD, year) 64.4 ± 10.6 61.9 ± 11.4 < 0.001
Male [(n) %] 175 (66.0) 199 (66.3) 0.941
AJCC Stage (IV/III/II/I/NA) 23/103/91/41/7 77/95/98/30/0 < 0.001
AJCC PT (T4/T3/T2/T1/NA) 66/121/62/16/0 21/91/188/0/0 < 0.001
AJCC PN (N4/N3/N2/N1/N0/NA) 4/49/55/67/88/2 0/51/80/131/38/0 0.011
AJCC PM (M2/M1/M0/NA) 9/13/243/0 0/27/273/0 0.869
Targeted molecular therapy (yes/no/NA) 78/79/108 NA  
Radiation treatment adjuvant (yes/no/NA) 0/155/110 NA  
History other malignancy (yes/no/NA) 6/259/0 NA  
Barretts esophagus (yes/no/NA) 12/151/102 NA  
H pylori infection (yes/no/NA) 15/117/133 NA  
  1. Continuous variables were compared by t-test or Mann–Whitney U test as appropriate; categorical variables were compared by Chi squared test or Fisher’s exact test as appropriate
  2. NA, missing data; SD: standard deviation; AJCC: American Joint Committee on Cancer